Last week, oil drilling equipment maker Cameron International Corp. (CAM) closed the previously announced acquisition of Texas-based fellow oilfield service provider NATCO Group for approximately $780 million, following the approval by NATCO’s shareholders.  In relation to the acquisition, Cameron reached an agreement with the U.S. Department of Justice (DOJ) to divest its Edge refinery desalter business and will license, on a non-exclusive basis, NATCO's Dual Frequency electrostatic technology for refinery desalter products. This was based on the DOJ’s antitrust division’s view that the acquisition as originally proposed would significantly hamper U.S. refinery desalter manufacturing competition, resulting in higher prices and lower quality, service, and innovation.  Incidentally, Cameron and NATCO are the top two domestic refinery desalter suppliers. The acquiistion involved an all-stock transaction whereby, NATCO stakeholders exchanged each of their shares for 1.185 Cameron common stocks and will receive cash reflecting the value of any fractional shares. ...

For Immediate Release

Chicago, IL – November 11, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Boston Scientific Corporation (BSX), Johnson & Johnson (JNJ), Medtronic Inc. (MDT), Abbott Laboratories (ABT) and St. Jude Medical Inc. (STJ).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Tuesday’s Analyst Blog:

BSX Settles, Lowers Results

Boston Scientific Corporation (BSX) settled its $296 million lawsuit with the U.S. Department of Justice (DOJ) related to product advisories issued by its Guidant subsidiary in 2005. The litigation pertained to alleged violations of the Food, Drug, and Cosmetic

...

For Immediate Release

Chicago, IL – November 11, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AT&T Inc (T), Centennial Communications Corp (CYCL), Verizon (VZ), JA Solar Holdings Co. Ltd. (JASO) and AutoNation (AN).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Tuesday’s Analyst Blog:

AT&T Completes CYCL Acquisition

AT&T Inc (T) has reportedly completed its much anticipated acquisition of Centennial Communications Corp (CYCL), the eighth largest US wireless carrier by subscribers. This follows the recent approvals of the transaction by the US Department of Justice and US

...

Boston Scientific Corporation (BSX) settled its $296 million lawsuit with the U.S. Department of Justice (DOJ) related to product advisories issued by its Guidant subsidiary in 2005. The litigation pertained to alleged violations of the Food, Drug, and Cosmetic Act by Guidant. The allegations were reported prior to Boston’s acquisition of Guidant in 2006. Boston has recorded the litigation expense in its third quarter of fiscal 2009 results and updated its income statement accordingly. The expense has lowered the company’s GAAP earnings per share by 19 cents into a loss per share of 6 cents in the third quarter of 2009. Adjusted figures remained unaffected by this charge. Boston has also lowered its full fiscal 2009 GAAP earnings per share guidance to a range of 23 to 28 cents, compared to its prior guidance of 43 to 48 cents. The company’s adjusted earnings per share guidance ...

AT&T Inc (T) has reportedly completed its much anticipated acquisition of Centennial Communications Corp (CYCL), the eighth largest US wireless carrier by subscribers. This follows the recent approvals of the transaction by the US Department of Justice and US telecom regulator Federal Communications Commission (“FCC"). The transaction, which was originally set to complete in second-quarter 2009, is now officially closed.  As per the agreement terms, shareholders of Centennial will receive $8.50 in cash for every share they own, equating to approximately $944 million. Including net debt, the aggregate value of the deal is $2.7 billion. AT&T will take appropriate steps to redeem all of Centennial’s outstanding debts. AT&T expects minimal dilution to earnings and cash flow in 2009 given the upfront integration costs.  The acquisition has expanded AT&T’s wireless coverage to include the rural areas of the Midwest and Southeast regions of the US as ...

API Nanotronics Corp., a prime contractor for secure communications and electronic components to the global defense and aerospace industry announced operating results for the first quarter of fiscal 2010 ended August 31, 2009.

Financial Highlights:

– Net revenue for the first quarter of fiscal 2010 was $9.2 million, a 16% increase over fiscal 2009 first quarter revenue of $7.9 million. This revenue includes the contribution from Cryptek as at the date of the acquisition on July 07, 2009;

– First quarter Gross Profit increased to $2.3 million in the first quarter of fiscal 2010 compared to $2.1 million in the first quarter of fiscal 2009. Gross Margins in the company’s electronic component and sub-system product lines improved by 4% to 30.3% on a year-over-year basis due to rationalization and efficiency efforts undertaken during fiscal 2009;

– GAAP net loss for the quarter was $0.8 million or $0.02 per share, compared to a loss of

...

Recently, Mylan (MYL) announced the settlement of its dispute with Pfizer (PFE) related to the patent of antifungal drug Vfend (voriconazole). Now Mylan can launch an authorized generic version of the drug in two dosage forms of 50 mg and 200 mg tablets in early 2011. Mylan’s subsidiary, Matrix Laboratories, has Food and Drug Administration (FDA) approval for the generic version of the drug. Being the first company to submit an Abbreviated New Drug Application (ANDA), Matrix expects to be eligible to receive 180 days of marketing exclusivity for the drug. However, the agreement does not include liquid or intravenous versions of Vfend. The agreement has yet to be approved by the US Department of Justice and the Federal Trade Commission. Vfend recorded sales of $164 million in the 12 months ended June 30. Mylan received quite a few approvals in the past few ...

AT&T Inc’s (T) much anticipated acquisition of regional wireless and wireline service provider Centennial Communications Corp (CYCL), has progressed a step further as the US wireless giant has reportedly received a conditional approval of the US Department of Justice (“DOJ").  The acquisition is now subject to the approval of the US telecom regulator Federal Communications Commission. The US antitrust approval is based on fulfillment of specific conditions which requires AT&T to divest certain Centennial assets in eight markets across Louisiana (central and southern) and southwestern Mississippi .  This is due to the fact that the acquisition may potentially hurt consumer interest in these regions. As part of this requirement, AT&T has already committed to sell wireless assets in five of the eight markets to its rival operator Verizon (VZ) for $240 million. AT&T announced its acquisition of Centennial for approximately $2.8 billion (including net debt) ...

The world’s largest drugmaker Pfizer (PFE) now leads the list of largest healthcare fraud settlement payers. The company yesterday announced that it finalized with the U.S. Department of Justice (DoJ) to pay a total of $2.3 billion in penalty. The penalty is related to its off-label promotional practices for Bextra, and other fraudulent marketing practices for the promotion of four drugs. Pfizer also entered into an integrity agreement with the Health and Human Services Department under which it has agreed to ensure proper checks for a period of five years in order to avoid such issues.

In 2005, Bextra was voluntarily withdrawn from the market as it was illegally promoted for several unapproved indications and dosages. In order to resolve the matter, Pfizer agreed to pay a criminal fine of $1.3 billion, which is the largest criminal fine ever imposed in the U.S. In addition, the company agreed to pay

...

For Immediate Release

Chicago, IL – August 24, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Oracle Corp. (ORCL), Sun Microsystems, Inc. (JAVA), International Business Machines Corp. (IBM), Hewlett-Packard (HPQ) and Cisco Systems Inc. (CSCO).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Friday’s Analyst Blog:

Oracle Gets Approval to Buy Sun

The largest software company, Oracle Corp. (ORCL) announced that the U.S. Department of Justice (DOJ) has approved its proposed acquisition of Sun Microsystems, Inc. (JAVA). The approval from the DOJ was much anticipated.

In June,

...